Literature DB >> 12829841

The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta.

Masahiro Fujimuro1, S Diane Hayward.   

Abstract

The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV) is expressed in all KSHV-associated malignancies. LANA is essential for replication and maintenance of the viral episomes during latent infection. However, LANA also has a transcriptional regulatory role and can affect gene expression both positively and negatively. A previously performed yeast two-hybrid screen identified glycogen synthase kinase 3 (GSK-3) as a LANA-interacting protein. Interaction with both GSK-3alpha and GSK-3beta was confirmed in transfected cells with coprecipitation assays. GSK-3beta also interacted with the herpesvirus saimiri homolog ORF73. GSK-3beta is an intermediate in the Wnt signaling pathway and a negative regulator of beta-catenin. In transfected cells, LANA was shown to overcome GSK-3beta-mediated degradation of beta-catenin. Examination of primary effusion lymphoma (PEL) cells found increased levels of beta-catenin relative to KSHV-negative B cells, and this translated into increased activity of a beta-catenin-responsive reporter containing Tcf/Lef binding sites. In tetradecanoyl phorbol acetate-treated PEL cells, loss of LANA expression correlated temporally with loss of detectable beta-catenin. LANA was found to alter the intracellular distribution of GSK-3beta so that nuclear GSK-3beta was more readily detectable in the presence of LANA. Mapping experiments with coimmunoprecipitation assays revealed that both N-terminal and C-terminal LANA sequences were required for efficient GSK-3beta interaction. LANA mutants that were defective for GSK-3beta interaction were unable to mediate GSK-3beta relocalization or activate a beta-catenin-responsive Tcf-luciferase reporter. This study identified manipulation of GSK-3beta activity as a mechanism by which LANA may modify transcriptional activity and contribute to the phenotype of primary effusion lymphoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829841      PMCID: PMC161926          DOI: 10.1128/jvi.77.14.8019-8030.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

1.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

Review 2.  Wnt signaling and cancer.

Authors:  P Polakis
Journal:  Genes Dev       Date:  2000-08-01       Impact factor: 11.361

3.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  C Parravicini; B Chandran; M Corbellino; E Berti; M Paulli; P S Moore; Y Chang
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Detection of the human herpesvirus 8-encoded cyclin protein in primary effusion lymphoma-derived cell lines.

Authors:  G M Platt; E Cannell; M E Cuomo; S Singh; S Mittnacht
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

5.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

Review 6.  Viral cyclins.

Authors:  S Mittnacht; C Boshoff
Journal:  Rev Med Virol       Date:  2000 May-Jun       Impact factor: 6.989

Review 7.  Control of beta-catenin signaling in tumor development.

Authors:  J Behrens
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

8.  Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease.

Authors:  H Katano; Y Sato; T Kurata; S Mori; T Sata
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

9.  Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding.

Authors:  M T Webster; M Rozycka; E Sara; E Davis; M Smalley; N Young; T C Dale; R Wooster
Journal:  Genes Chromosomes Cancer       Date:  2000-08       Impact factor: 5.006

10.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

View more
  74 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

3.  Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins.

Authors:  Huaxin Si; Subhash C Verma; Erle S Robertson
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 4.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

5.  Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway.

Authors:  Ke Lan; Daniel A Kuppers; Erle S Robertson
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus.

Authors:  Mark A Samols; Jianhong Hu; Rebecca L Skalsky; Rolf Renne
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA.

Authors:  Meir Shamay; Anita Krithivas; Jun Zhang; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

8.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function.

Authors:  Huaxin Si; Erle S Robertson
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

9.  Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus.

Authors:  Mandana Mansouri; Patrick P Rose; Ashlee V Moses; Klaus Früh
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 10.  Molecular mechanisms of viral oncogenesis in humans.

Authors:  Nathan A Krump; Jianxin You
Journal:  Nat Rev Microbiol       Date:  2018-11       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.